

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended December 31, 2013

OR

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number 001-31668

INTEGRATED BIOPHARMA, INC.

(Exact name of registrant, as specified in its charter)

Delaware

*(State or other jurisdiction of
incorporation or organization)*

22-2407475

*(I.R.S. Employer
Identification No.)*

225 Long Ave., Hillside, New Jersey

(Address of principal executive offices)

07205

(Zip Code)

(888) 319-6962

(Registrant's telephone number, including Area Code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Applicable only to Corporate Issuers:

The number of shares outstanding of each of the issuer's class of common stock, as of the latest practicable date:

Class
Common Stock, \$0.002 par value

Outstanding at February 12, 2014
21,080,174 Shares

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

**FORM 10-Q QUARTERLY REPORT
For the Six Months Ended December 31, 2013
INDEX**

	<u>Page</u>	
Part I. Financial Information		
Item 1.	Condensed Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2013 and 2012 (unaudited)	2
	Condensed Consolidated Balance Sheets as of December 31, 2013 and June 30, 2013 (unaudited)	3
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2013 and 2012 (unaudited)	4
	Notes to Condensed Consolidated Statements	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	23
Item 4.	Controls and Procedures	23
Part II. Other Information		
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosure	24
Item 5.	Other Information	24
Item 6.	Exhibits	24
	Other	
Signatures		25

Disclosure Regarding Forward-Looking Statements

Certain statements in this Quarterly Report on Form 10-Q may constitute “forward-looking” statements as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Act of 1934, as amended (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission, all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Integrated BioPharma, Inc. (the “Company”) or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words, “plan”, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “project”, “may”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to”, or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. The Company cautions investors that any forward-looking statements made by the Company are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to the Company, include, but are not limited to, the risks and uncertainties affecting its businesses described in Items 1 and 1A of the Company’s Annual Report filed on Form 10-K for the year ended June 30, 2013 and in registration statements and other securities filings by the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any of the forward-looking statements and are subject to change due inherent risks and uncertainties. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made only as of the date hereof and the Company does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

ITEM 1. FINANCIAL STATEMENTS

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except for share and per share amounts)
(Unaudited)

	Three months ended		Six months ended	
	December 31,		December 31,	
	2013	2012	2013	2012
Sales, net	\$ 8,788	\$ 7,395	\$ 17,979	\$ 15,875
Cost of sales	7,319	6,256	14,913	13,171
Gross profit	1,469	1,139	3,066	2,704
Selling and administrative expenses	850	1,108	1,787	2,305
Operating income	619	31	1,279	399
Other income (expense), net				
Change in fair value of derivative liabilities	82	656	9	(428)
Other income, net	3	380	5	374
Interest expense	(246)	(239)	(494)	(487)
Other income (expense), net	(161)	797	(480)	(541)
Income (loss) before income taxes	458	828	799	(142)
Income tax expense, net	61	11	104	13
Net income (loss)	397	817	695	(155)
Interest expense on Convertible debt-CD Financial, LLC	82	82	164	-
Accretion of Convertible debt - CD Financial, LLC	27	27	54	-
Diluted net income (loss)	<u>\$ 506</u>	<u>\$ 926</u>	<u>\$ 913</u>	<u>\$ (155)</u>
Basic net income (loss) per common share	<u>\$ 0.02</u>	<u>\$ 0.04</u>	<u>\$ 0.03</u>	<u>\$ (0.01)</u>
Diluted net income (loss) per common share	<u>\$ 0.02</u>	<u>\$ 0.03</u>	<u>\$ 0.03</u>	<u>\$ (0.01)</u>
Weighted average common shares outstanding - basic	21,080,174	21,080,174	21,080,174	21,080,174
Add: Stock options	73,012	219,581	37,017	-
Shares issuable upon conversion of				
Convertible Debt - CD Financial, LLC	8,230,769	8,230,769	8,230,769	-
Weighted average common shares outstanding - diluted	<u>29,383,955</u>	<u>29,530,524</u>	<u>29,347,960</u>	<u>21,080,174</u>

See accompanying notes to condensed consolidated financial statements.

INTEGRATED BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except for share and per share amounts)
(Unaudited)

	December 31, 2013	June 30, 2013
Assets		
Current Assets:		
Cash	\$ 135	\$ 55
Accounts receivable, net	2,289	2,419
Inventories	5,800	6,431
Investment in iBio, Inc. - restricted	684	684
Other current assets	331	339
Total current assets	9,239	9,928
Intangible assets, net	948	1,017
Property and equipment, net	1,205	1,235
Security deposits and other assets	374	431
Total Assets	\$ 11,766	\$ 12,611
Liabilities and Stockholders' Deficiency:		
Current Liabilities:		
Advances under revolving credit facility	\$ 4,234	\$ 4,543
Accounts payable (includes \$126 and \$186 due to related party)	5,049	5,883
Accrued expenses and other current liabilities	1,190	1,122
Current portion of long term debt	598	868
Total current liabilities	11,071	12,416
Long term debt	4,647	4,888
Subordinated convertible note, net - CD Financial LLC	4,955	4,901
Derivative liabilities	687	696
Total liabilities	21,360	22,901
Commitments and Contingencies		
Stockholders' Deficiency:		
Common Stock, \$0.002 par value; 50,000,000 shares authorized; 21,115,074 and 21,080,174 shares issued and outstanding, respectively	42	42
Additional paid-in capital	44,568	44,568
Accumulated deficit	(54,105)	(54,801)
Less: Treasury stock, at cost, 34,900 shares	(99)	(99)
Total Stockholders' Deficiency	(9,594)	(10,290)
Total Liabilities and Stockholders' Deficiency	\$ 11,766	\$ 12,611

See accompanying notes to condensed consolidated financial statements.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, except share and per share amounts)
(Unaudited)

	Six months ended	
	December 31,	
	2013	2012
Cash flows used in operating activities:		
Net income (loss)	\$ 695	\$ (155)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization	203	213
Accretion of financing instruments and amortization of prepaid financing costs	119	113
Change in fair value of derivative liabilities	(9)	428
(Gain) loss on sale of fixed assets	(4)	6
Changes in assets and liabilities:		
Decrease (increase) in:		
Accounts receivable	130	(923)
Inventories	631	(1,203)
Other current assets	8	59
Security deposits and other assets	(8)	47
(Decrease) increase in:		
Accounts payable	(834)	547
Accrued expenses and other liabilities	69	(111)
Net cash provided by (used in) operating activities	<u>1,000</u>	<u>(979)</u>
Cash flows from investing activities:		
Purchase of property and equipment	(29)	(8)
Proceeds from sale of property and equipment	-	18
Net cash (used in) provided by investing activities	<u>(29)</u>	<u>10</u>
Cash flows from financing activities:		
Advances under revolving credit facility	17,518	17,076
Repayments under revolving credit facility	(17,827)	(15,902)
Payments under term notes	(564)	(226)
Payments under capital lease obligations	(18)	-
Net cash (used in) provided by financing activities	<u>(891)</u>	<u>948</u>
Net increase (decrease) in cash	80	(21)
Cash at beginning of period	55	145
Cash at end of period	<u>\$ 135</u>	<u>\$ 124</u>
Supplemental disclosures of cash flow information:		
Cash paid during the periods for:		
Interest	<u>\$ 361</u>	<u>\$ 298</u>
Income taxes	<u>\$ 5</u>	<u>\$ 13</u>
Assets purchased under capitalized lease obligations	<u>\$ 76</u>	<u>\$ -</u>

See accompanying notes to condensed consolidated financial statements.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

Note 1. Principles of Consolidation and Basis of Presentation

Basis of Presentation of Interim Financial Statements

The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013 (“Form 10-K”), as filed with the SEC. The June 30, 2013 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results of operations for the three and six months ended December 31, 2013 are not necessarily indicative of the results for the full fiscal year ending June 30, 2014 or for any other period.

Nature of Operations

The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.

The Company’s business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers, under the following brands: Naturally Noni, Naturally Pomegranate, Pomegranate with ACAI and Reservatrol, Coconut Water, Naturally Aloe, Aloe Pure, Peaceful Sleep, Green Envy, ACAI Extra, ACAI Immune, ACAI Cleanse, and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement and (iii) Chem International, Inc., a distributor of certain raw materials for DSM Nutritional Products, Inc.

Significant Accounting Policies

There have been no material changes during fiscal year 2014 in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013.

Investment in iBio, Inc.- Restricted. The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008. The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. There was an impairment charge of \$139 recorded in the quarter ended March 31, 2013. Although the market value of the

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

iBio Stock as of December 31, 2013 was approximately \$0.4 million, a trading price below the carrying value per share as of December 31, 2013 and other points in time, management's assessment concluded that there is no reason to believe that such declines are other than temporary as of the reporting date. Pursuant to the Company's Loan Agreement with PNC Bank, National Association ("PNC"), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than \$0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. In the fiscal year ended June 30, 2013, the trading price of the iBio Stock was less than \$0.88 for a period of fifteen (15) consecutive trading days and has continued to have a trading price less than \$0.88 through February 12, 2014. (See Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt). As of December 31, 2013, the Company has not sold any shares of the iBio Stock. As of February 12, 2014, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future.

Earnings Per Share. Basic earnings per common share amounts are based on the weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, and warrants, subject to anti-dilution limitations using the treasury stock method and the assumed conversion shares of all potentially dilutive convertible notes payable subject to anti-dilution limitations using the if converted method.

The following options, warrants and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three and six months ended December 31, 2013 and 2012:

	Three Months Ended		Six Months Ended	
	December 31,		December 31,	
	<u>2013</u>	<u>2012</u>	<u>2013</u>	<u>2012</u>
Anti-dilutive stock options	1,252,770	2,176,588	1,252,770	2,811,088
Anti-dilutive warrants	-	500,000	-	500,000
Potentially dilutive shares				
of convertible notes payable	-	-	-	8,230,769
Total anti-dilutive shares	<u>1,252,770</u>	<u>2,676,588</u>	<u>1,252,770</u>	<u>11,541,857</u>

Stock options to purchase or otherwise obtain 634,500 shares of common stock of the Company, however, were included in the diluted earnings per share computation for earnings per share in the three month period ended December 31, 2012 as their exercise prices were less than the market price of the common shares as of December 31, 2012.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

Note 2. Inventories

Inventories are stated at the lower of cost or market using the first-in, first-out method and consist of the following as of:

	December 31, 2013	June 30, 2013
Raw materials	\$ 3,077	\$ 2,512
Work-in-process	871	1,979
Finished goods	1,852	1,940
Total	\$ 5,800	\$ 6,431

Note 3. Intangible Assets, net

Intangible assets consist of trade names, license fees from the Branded Proprietary Products Segment, and unpatented technology from the Other Nutraceutical Businesses Segment. The carrying amount of intangible assets, net is as follows as of:

	December 31, 2013			June 30, 2013		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Trade names and patents	\$ 1,525	\$ 777	\$ 748	\$ 1,525	\$ 739	\$ 786
Unpatented technology	547	480	67	547	460	87
License agreement	347	214	133	347	203	144
Total	\$ 2,419	\$ 1,471	\$ 948	\$ 2,419	\$ 1,402	\$ 1,017

Amortization expense recorded on intangible assets for each of the three and six months ended December 31, 2013 and 2012 was \$34 and \$69, respectively. Amortization expense is recorded on the straight-line basis over periods ranging from 10 years to 20 years based on contractual or estimated lives and is included in selling and administrative expenses.

The estimated annual amortization expense for intangible assets for the five succeeding fiscal years is as follows:

Year ending June 30,	Amortization Expense
2014, remaining	\$ 68
2015	137
2016	104
2017	97
2018	97
2019	97
Thereafter	348
Total	\$ 948

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

Note 4. Property and Equipment, net

Property and equipment, net consists of the following as of:

	December 31, 2013	June 30, 2013
Land and building	\$ 1,250	\$ 1,250
Leasehold improvements	1,138	1,132
Machinery and equipment	4,945	4,918
Transportation equipment	59	59
	<u>7,392</u>	<u>7,359</u>
Less: Accumulated depreciation and amortization	(6,187)	(6,124)
Total	<u>\$ 1,205</u>	<u>\$ 1,235</u>

Depreciation and amortization expense was \$66 and \$71 for the three months ended December 31, 2013 and 2012, respectively and \$135 and \$144 for the six months ended December 31, 2013 and 2012, respectively. In the three and six months ended December 31, 2013, the Company traded in property and equipment with an original cost of \$76 for a cash discount of \$4 on the replacement property, resulting in a gain on disposal of \$4. In the three and six months ended December 31, 2012, the Company disposed of property and equipment with an original cost of \$188 for net proceeds of \$18.

Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt

As of December 31 and June 30, 2013, the Company had the following debt outstanding:

	Principal Amount		Interest Rate	Maturity Date
	As of December 31, 2013	As of June 30, 2013		
Revolving advances under Senior Credit Facility with PNC Bank, National Association	\$ 4,234	\$ 4,543	3.25%	6/27/2017
Installment Note with PNC Bank	2,679	3,239	3.75%	6/27/2017
Promissory Note with CD Financial, LLC	1,714	1,714	6.00%	7/7/2017
Promissory Note with Vitamin Realty, LLC	686	686	4.00%	7/7/2017
			5.30% -	2/28/2015 -
Capitalized lease obligations	111	58	7.10%	11/20/2016
Promissory Note with E. Gerald Kay	27	27	4.00%	7/7/2017
Promissory Note with Acura Financial Services	28	32	1.90%	4/15/2017
Total outstanding debt	<u>9,479</u>	<u>10,299</u>		
Less: Revolving Advances	(4,234)	(4,543)		
Current portion of long term debt	(598)	(868)		
Long term debt	<u>\$ 4,647</u>	<u>\$ 4,888</u>		
Convertible Note payable - CD Financial, LLC	\$ 5,350	\$ 5,350	6.00%	7/7/2017
Unamortized discount for embedded derivative	(395)	(449)		
Convertible Note payable, net - CD Financial, LLC	<u>\$ 4,955</u>	<u>\$ 4,901</u>		

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

SENIOR CREDIT FACILITY

On June 27, 2012, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (“IHT Properties”) and Vitamin Factory (collectively, the “Borrowers”) entered into a Revolving Credit, Term Loan and Security Agreement (the “Loan Agreement”) with PNC as agent and lender and the other lenders party thereto.

The Loan Agreement provides for a total of \$11,727 in senior secured financing (the “Senior Credit Facility”) as follows: (i) discretionary advances (“Revolving Advances”) based on eligible accounts receivable and eligible inventory in the maximum amount of \$8,000 (the “Revolving Credit Facility”) and (ii) a term loan in the amount of \$3,727 (the “Term Loan”). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and the iBio Stock owned by the Company. Revolving Advances bear interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 2.75% (3.25% as of December 31 and June 30, 2013). The Term Loan bears interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 3.25% (3.75% as of December 31 and June 30, 2013). Upon and after the occurrence of any event of default under the Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on June 27, 2017 (the “Senior Maturity Date”).

The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in sixty (60) consecutive monthly installments of principal, the first fifty nine (59) of which shall be in the amount of \$44, commencing on the first business day of August, 2012, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the first business day of July, 2017. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof.

The Revolving Advances are subject to the terms and conditions set forth in the Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) \$8.0 million or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Loan Agreement, of eligible accounts receivables (“Receivables Advance Rate”), plus (ii) up to the lesser of (A) 65%, subject to the provisions in the Loan Agreement, of the value of the eligible inventory (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), minus (iii) the aggregate Maximum Undrawn Amount of all outstanding Letters of Credit, minus (iv) such reserves as Agent may reasonably deem proper and necessary from time to time.

The Loan Agreement contains customary mandatory prepayment provisions, including, without limitation, (i) the requirement that if the trading price per share of the iBio Stock falls below a certain amount, the Company shall sell the iBio Stock and use the proceeds to repay the Term Loan and (ii) the requirement to prepay loans in an amount equal to fifty percent (50%) of Excess Cash Flow for each fiscal year commencing with the fiscal year ending June 30, 2013, payable upon delivery of the financial statements to PNC referred to in and required by the Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which prepayment amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof until the aggregate amount of payments made with regard to the Term Loan pursuant to Loan Agreement equals \$1.0 million. The Loan Agreement also contains customary representations and warranties, covenants and events

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Loan Agreement. As of December 31, 2013, the Company is in compliance with the fixed charge coverage ratio maintenance requirement.

During certain periods in the fiscal year ended June 30, 2013 and continuing into the six months ended December 31, 2013, the trading price of the iBio Stock was less than \$0.88 for a period of fifteen (15) consecutive trading days. However, PNC temporarily waived the requirement to sell the iBio Stock due to certain trading rules and restrictions under Rule 144 under the Securities Act of 1933, as amended. As of February 12, 2014, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future.

In October, 2013, when the Company delivered its annual financial statements for the fiscal year ended June 30, 2013 to PNC, as required under the Loan Agreement, the Company was required to make a prepayment in respect of loans outstanding under the Loan Agreement of approximately \$293, representing 50% of Excess Cash Flows for the fiscal year ended June 30, 2013. This payment, along with the scheduled monthly principal payments of \$44 made by the Company in respect of the Term Loan through November 1, 2013 provided for principal payments of \$1.0 million in the aggregate.

In connection with the Senior Credit Facility, each of E. Gerald Kay, an officer, director and major stockholder of the Company, and Carl DeSantis, a director and major stockholder of the Company (collectively, the “Guarantors”), entered into Continuing Limited Guarantees (collectively, the “Individual Guarantees”) with PNC whereby each Guarantor irrevocably and unconditionally guarantees the full, prompt and unconditional payment, when due, whether by acceleration or otherwise, of any and all obligations of the Borrowers under the Loan Agreement and the other loan documents. The liability of each Guarantor under his respective Individual Guarantee is limited to a maximum of \$1.0 million. The Individual Guarantees automatically terminate upon the satisfaction of certain conditions set forth in the Loan Agreement. These conditions included the Company repaying an aggregate amount of \$1.0 million of principal on the Term Loan and the Company meeting a minimum EBITDA, as defined in the Loan Agreement, of \$1.5 million for the fiscal year ended June 30, 2013. The Company met these requirements on November 1, 2013 and Mr. DeSantis and Mr. Kay were released as guarantors under the Individual Guarantees.

Also, in connection with the Senior Credit Facility, PNC and CD Financial, LLC (“CD Financial”) entered into the Intercreditor and Subordination Agreement (the “Intercreditor Agreement”), which was acknowledged by the Borrowers, pursuant to which, among other things, (a) the lien of CD Financial on assets of the Borrowers is subordinated to the lien of PNC on such assets during the effectiveness of the Senior Credit Facility, and (b) priorities for payment of the debt for the Company and its subsidiaries (as described in this Note 5) are established.

In addition, in connection with the Senior Credit Facility, the following loan documents were executed: (i) the Company has entered into a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) IHT Properties has entered into a Mortgage and Security Agreement with PNC; and (iii) the Borrowers have entered into an Environmental Indemnity Agreement with PNC.

CD FINANCIAL, LLC DEBT

On June 27, 2012, the Company also entered into an Amended and Restated Securities Purchase Agreement (the “CD SPA”) with CD Financial, which amended and restated the Securities Purchase Agreement, dated as of February 21, 2008, between the Company and CD Financial, pursuant to which the Company issued to CD Financial a 9.5% Convertible Senior Secured Note in the original principal amount of \$4,500 (the “Original CD Note”). Pursuant to the CD SPA, the Company issued to CD Financial (i) the Amended and Restated Convertible Promissory Note in the principal amount of \$5,350 (the “CD Convertible Note”) and (ii) the Promissory Note in the principal amount of \$1,714 (the “Liquidity Note”, and collectively with the CD Convertible Note, the “CD Notes”). The CD Notes mature on July 7, 2017.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

The CD Notes are secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and iBio Stock owned by the Company. The CD Notes bear interest at an annual rate of 6% and have a default rate of 10%.

The CD Convertible Note is convertible at the option of CD Financial into common stock of the Company at a conversion price of \$0.65 per share, subject to customary adjustments including conversion price protection provisions.

Pursuant to the terms of the Loan Agreement and the Intercreditor Agreement, during the effectiveness of the Senior Credit Facility, (i) the principal of the CD Convertible Note may not be repaid, (ii) the principal of the Liquidity Note may only be repaid if certain conditions under the Loan Agreement are satisfied, and (iii) interest in respect of the CD Notes may only be paid if certain conditions under the Intercreditor Agreement are satisfied.

The CD SPA contains customary representations and warranties, covenants and events of default, including, without limitation, an event of default tied to any change of control as defined in the CD SPA.

In connection with the CD SPA, the Borrowers entered into an Amended and Restated Security Agreement and Amended and Restated Subsidiary Guaranty.

As of December 31 and June 30, 2013, the related embedded derivative liability with respect to conversion price protection provisions on the CD Convertible Note has an estimated fair value of \$687 and \$696, respectively.

The Company used the following assumptions to calculate the fair value of the derivative liability using the Black-Scholes option pricing model:

	December 31, 2013	June 30, 2013	Issuance Date- June 27, 2012
Risk Free Interest Rate	0.78%	0.66%	0.72%
Volatility	102.10%	118.50%	144.10%
Term	3.5 years	4 years	5 years
Dividend Rate	0.00%	0.00%	0.00%
Closing Price of Common Stock	\$ 0.19	\$ 0.15	\$ 0.09

OTHER LONG TERM DEBT

On June 27, 2012, MDC and the Company entered into separate promissory notes with (i) Vitamin Realty Associates, LLC (“Vitamin Realty”), which is 90% owned by E. Gerald Kay, the Company’s Chairman of the Board, President and major shareholder and certain of his family members, who are also executive officers and directors of the Company, and (ii) E. Gerald Kay, in the principal amounts of approximately \$686 (the “Vitamin Note”) and \$27 (the “Kay Note”), respectively (collectively the “Related Party Notes”). The principal amount of the Vitamin Note represents the aggregate amount of unpaid, past due rent owing by MDC under the Lease Agreement, dated as of January 10, 1997, between MDC, as lessor, and Vitamin Realty, as landlord, pertaining to the real property located at 225 Long Avenue, Hillside, New Jersey. (See Note 7. Commitments and Contingencies (a) Leases – Related Parties). The Kay Note represents amounts owed to Mr. Kay for unreimbursed business expenses incurred by Mr. Kay in the fiscal year ended June 30,

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

2008. The Related Party Notes mature on July 7, 2017 and accrue interest at an annual rate of 4% per annum. Interest in respect of the Related Party Notes is payable on the first business day of each calendar month. Pursuant to the terms of the Loan Agreement, during the effectiveness of the Senior Credit Facility, the Related Party Notes may only be repaid or prepaid if certain conditions set forth in the Loan Agreement are satisfied.

Note 6. Significant Risks and Uncertainties

(a) Major Customers. For the three and six months ended December 31, 2013, approximately 82% and 80%, respectively of total net sales were derived from two customers in the Company's contract manufacturing segment as compared to approximately 73% and 72% of total net sales derived from the same two customers in the Company's contract manufacturing segment in the three and six months ended December 31, 2012, respectively. Accounts receivable as of December 31, 2013 from these customers represented approximately 74% of total accounts receivable. The loss of any of these two customers would have an adverse affect on the Company's operations. Major customers are those customers who account for more than 10% of net sales.

(b) Other Business Risks. Approximately 63% the Company's employees are covered by a union contract and are employed in its New Jersey facilities. The union contract was renewed in May 2012 and expires in August 2015.

Note 7. Commitments and Contingencies

(a) Leases

Related Party Leases. Warehouse and office facilities are leased from Vitamin Realty. On January 5, 2012, MDC, a wholly-owned subsidiary of the Company, entered into a second amendment of lease (the "Second Lease Amendment") with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026. This Second Lease Amendment provides for minimum annual rental payments of \$533, plus increases in real estate taxes and building operating expenses. Also on January 5, 2012, AgroLabs entered into a lease agreement with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which expires on January 31, 2019. This additional lease provides for minimum lease payments of \$27 with annual increases plus the proportionate share of operating expenses.

Rent expense for the three and six months ended December 31, 2013 and 2012 on these leases were \$201 and \$196 and \$407 and \$391, respectively, and are included in both cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. As of December 31, 2013 and June 30, 2013, the Company had an outstanding obligation to Vitamin Realty of \$845 and \$918, respectively, included in accounts payable and long term debt in the accompanying Condensed Consolidated Balance Sheet.

Other Lease Commitments. The Company has entered into certain non-cancelable operating lease agreements expiring up through January 31, 2026, related to office and warehouse space, equipment and vehicles.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

The minimum rental commitment for long-term non-cancelable leases is as follows:

Year ending June 30,	Lease Commitment	Related Party Lease Commitment	Total
2014, remaining	\$ 27	\$ 281	\$ 308
2015	45	563	608
2016	35	563	598
2017	15	563	578
2018	8	563	571
2019	-	550	550
Thereafter	-	3,510	3,510
Total	\$ 130	\$ 6,593	\$ 6,723

Total rent expense, including real estate taxes and maintenance charges, was approximately \$244 and \$239 and \$490 and \$500 for the three and six months ended December 31, 2013 and 2012, respectively. Rent expense is included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.

(b) Legal Proceedings.

The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company's liquidity, financial condition and cash flows.

(c) Other Claims.

On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent the Company a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company. In the Demand Letter, Cedarburg demanded payment by the Company of \$0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA. In addition, in the Demand Letter, Cedarburg informed the Company that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of \$0.3 million.

On May 30, 2012, the Company sent a letter responding to the Demand Letter and setting forth the Company's position that it has no obligation to indemnify Cedarburg as demanded. On June 18, 2012, Cedarburg responded to the Company's letter and, on July 27, 2012, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. On December 18, 2012, Cedarburg responded to the Company's letter and, on January 15, 2013, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. As of February 12, 2014, the Company has not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter. The Company intends to vigorously contest Cedarburg's demand as set forth in the Demand Letter.

Note 8. Related Party Transactions

On June 27, 2012, Carl DeSantis, a director and major shareholder of the Company and a member of CD Financial and E. Gerald Kay, the Company's Chief Executive Officer, Chairman of the Board, President and a major shareholder each entered into Limited Guaranty Agreements with PNC in the amount of \$1.0 million each.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

(See Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt).

Neither Mr. DeSantis nor Mr. Kay received any compensation from the Company in connection with these guarantees. The Individual Guarantees automatically terminate upon the satisfaction of certain conditions set forth in the Loan Agreement. These conditions included the Company repaying an aggregate amount of \$1.0 million of principal on the Term Loan and the Company meeting a minimum EBITDA, as defined in the Loan Agreement, of \$1.5 million for the fiscal year ended June 30, 2013. These two conditions were met by the Company on November 1, 2013 and Mr. DeSantis and Mr. Kay were released as guarantors under the Individual Guarantees.

See Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt for related party securities transactions.

See Note 7(a). Leases for related party lease transactions.

Note 9. Segment Information

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company's operating segments.

The Company has divided its operations into three reportable segments as follows: Contract Manufacturing, Branded Proprietary Products and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe and Canada, for the three months ended December 31, 2013 and 2012 were \$3,170 and \$3,125, respectively and for the six months ended December 31, 2013 and 2012 were \$6,256 and \$5,643, respectively.

Financial information relating to the three months ended December 31, 2013 and 2012 operations by business segment are as follows:

		Sales, Net			Segment Gross Profit	Depreciation	Capital Expenditures
		U.S. Customers	International Customers	Total			
Contract Manufacturing	2013	\$ 4,973	\$ 2,819	\$ 7,792	\$ 1,208	\$ 63	\$ 103
	2012	3,521	2,709	6,230	841	66	-
Branded Proprietary Products	2013	130	322	452	107	1	-
	2012	403	391	794	222	1	-
Other Nutraeutical Businesses	2013	515	29	544	154	2	2
	2012	346	25	371	76	4	-
Total Company	2013	5,618	3,170	8,788	1,469	66	105
	2012	4,270	3,125	7,395	1,139	71	-

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
(Unaudited)

Financial information relating to the six months ended December 31, 2013 and 2012 operations by business segment are as follows:

		Sales, Net			Segment Gross Profit	Depreciation	Capital Expenditures
		U.S. Customers	International Customers	Total			
Contract Manufacturing	2013	\$ 10,402	\$ 5,681	\$ 16,083	\$ 2,574	\$ 129	\$ 103
	2012	8,397	4,913	13,310	1,937	132	8
Branded Proprietary Products	2013	262	482	744	164	1	-
	2012	990	635	1,625	544	5	-
Other Nutraceutical Businesses	2013	1,059	93	1,152	328	5	2
	2012	845	95	940	223	7	-
Total Company	2013	11,723	6,256	17,979	3,066	135	105
	2012	10,232	5,643	15,875	2,704	144	8

	Total Assets as of	
	December 31, 2013	June 30, 2013
Contract Manufacturing	\$ 7,293	\$ 8,524
Branded Proprietary Products	2,125	2,186
Other Nutraceutical Businesses	2,348	1,901
Total Company	\$ 11,766	\$ 12,611

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Certain statements set forth under this caption constitute "forward-looking statements." See "Disclosure Regarding Forward-Looking Statements" on page 1 of this Quarterly Report on Form 10-Q for additional factors relating to such statements. The following discussion should also be read in conjunction with the condensed consolidated financial statements of the Company and Notes thereto included herein and the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2013.

The Company is engaged primarily in the manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company's customers are located primarily in the United States, Luxembourg and Canada.

Business Outlook

Our future results of operations and the other forward-looking statements contained in this Quarterly Report on Form 10-Q, including this MD&A, involve a number of risks and uncertainties, in particular, the statements regarding our goals and strategies, new product introductions, plans to cultivate new businesses, pending divestitures, future economic conditions, revenue, pricing, gross margin and costs, the tax rate, and potential legal proceedings. We are focusing our efforts to improve operational efficiency and reduce spending that may have an impact on expense levels and gross margin. In addition to the various important factors discussed above, a number of other important factors could cause actual results to differ significantly from our expectations. See the risks described in "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q.

We continue to focus on our core businesses and maintaining our cost structure in line with our sales. In our branded product segment, we continue to maintain and strengthen the relationships developed in the fiscal year ended June 30, 2013, which were focused primarily in the international markets of Canada, Mexico and Asia. We are also developing new products, including branded products for solid dosage, which will be manufactured by MDC and sold using our AgroLabs brand. We believe that this will increase sales and further leverage our fixed manufacturing and selling costs in each of these segments as we diversify our branded product offerings to our existing and prospective customers.

In the six months ended December 31, 2013, our income from operations was approximately \$1.3 million, which covered our debt service requirements and provided additional cash flows to pay the required principal payment on our Term Note with PNC as well as pay our suppliers on a more timely basis than we have been able to in the past.

Critical Accounting Policies and Estimates

There have been no changes to our critical accounting policies in the six months ended December 31, 2013. Critical accounting policies and the significant estimates made in accordance with them are regularly discussed by management with our Audit Committee. Those policies are discussed under "Critical Accounting Policies" in our "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in Item 7 of our Annual Report on Form 10-K for the year ended June 30, 2013.

Results of Operations

Our results from operations in the following table, sets forth the income statement data of our results as a percentage of net sales for the periods indicated:

	For the three months ended December 31,		For the six months ended December 31,	
	2013	2012	2013	2012
Sales, net	100.0%	100.0%	100.0%	100.0%
Costs and expenses:				
Cost of sales	83.3%	84.6%	82.9%	83.0%
Selling and administrative	9.7%	15.0%	9.9%	14.5%
	<u>93.0%</u>	<u>99.6%</u>	<u>92.9%</u>	<u>97.5%</u>
Income from operations	<u>7.0%</u>	<u>0.4%</u>	<u>7.1%</u>	<u>2.5%</u>
Other income (expense), net				
Change in fair value of derivative liabilities	0.9%	8.9%	0.1%	(2.7%)
Interest expense	(2.8%)	(3.2%)	(2.8%)	(3.1%)
Other income, net, primarily recovery	0.0%	5.1%	0.0%	2.4%
Other income (expense), net	<u>(1.8%)</u>	<u>10.8%</u>	<u>(2.7%)</u>	<u>(3.4%)</u>
Income (loss) before income taxes	5.2%	11.2%	4.4%	(0.9%)
Federal and state income taxes, net	<u>0.7%</u>	<u>0.2%</u>	<u>0.6%</u>	<u>0.1%</u>
Net income (loss)	<u>4.5%</u>	<u>11.0%</u>	<u>3.9%</u>	<u>(1.0%)</u>

For the Six Months Ended December 31, 2013 compared to the Six Months Ended December 31, 2012

Sales, net. Sales, net, for the six months ended December 31, 2013 and 2012 were \$18.0 million and \$15.9 million, respectively, an increase of 13%, and are comprised of the following:

	Six months ended December 31,		Dollar Change	Percentage Change
	2013	2012	2013 vs 2012	2013 vs 2012
	<i>(amounts in thousands)</i>			
Contract Manufacturing:				
US Customers	\$10,402	\$ 8,397	\$ 2,005	23.9%
International Customers	<u>5,681</u>	<u>4,913</u>	<u>768</u>	<u>15.6%</u>
Net sales, Contract Manufacturing	<u>16,083</u>	<u>13,310</u>	<u>2,773</u>	<u>20.8%</u>
Branded Nutraceutical Products:				
US Customers	262	990	(728)	(73.5%)
International Customers	482	635	(153)	(24.1%)
Net sales, Branded Nutraceutical Products	<u>744</u>	<u>1,625</u>	<u>(881)</u>	<u>(54.2%)</u>
Other Nutraceuticals:				
US Customers	1,059	845	214	25.3%
International Customers	<u>93</u>	<u>95</u>	<u>(2)</u>	<u>(2.1%)</u>
Net sales, Other Nutraceuticals	<u>1,152</u>	<u>940</u>	<u>212</u>	<u>22.6%</u>
Total net sales	<u>\$17,979</u>	<u>\$15,875</u>	<u>\$ 2,104</u>	<u>13.3%</u>

For the six months ended December 31, 2013, approximately 80% of total net sales were derived from two customers in our contract manufacturing segment as compared to approximately 72% of total net sales from the same two customers in our contract manufacturing segment for the six months ended December 31, 2012. The loss of either of these customers could have an adverse affect on our operations.

The increase in our net sales is primarily the result of an increase of approximately \$2.8 million in our contract manufacturing segment primarily due to increased sales volumes to our major customers in the six months ended December 31, 2013, of approximately \$3.0 million compared to the prior period, offset in part, by a decrease in the volume of sales in our branded proprietary products segment of \$0.9 million, primarily from our club store distribution channels.

Cost of sales. Cost of sales increased by \$1.7 million to \$14.9 million for the six months ended December 31, 2013, as compared to \$13.2 million for the six months ended December 31, 2012. Cost of sales as a percentage of net sales was substantial the same, approximately 83% for each of the six months ended December 31, 2013 and 2012. The increase in the cost of sales amount was primarily the result of increased sales, both sales and cost of sales increased by approximately 13%.

Selling and Administrative Expenses. Selling and administrative expenses were \$1.8 million for the six months ended December 31, 2013, as compared to \$2.3 million for the six months ended December 31, 2012, a decrease of approximately \$0.5 million or 22%. As a percentage of sales, net, selling and administrative expenses were 9.9% for the six months ended December 31, 2013 and 14.5% for the prior comparable period.

The net decrease in selling and administrative expenses of \$0.5 million is mainly due to decreases in advertising and other marketing expenses of \$0.3 million and professional and consulting fees of approximately \$0.1 million. Other selling and administrative expenses such as salaries and employee benefits, warehouse, office expenses and other expenses as a group decreased by approximately \$0.1 million, each individual classification decreased or increased by less than \$50,000 from the prior comparable period other than warehouse expenses which decreased by approximately \$63,000 as a result of closing our Texas warehouse facility in our branded nutraceutical products segment and consolidating other third party warehousing of this segment's inventory.

Our advertising and other marketing costs decreased by approximately \$0.3 million in the six months ended December 31, 2013 compared to the six months ended December 31, 2012 as a result of a decrease in in-store demonstrations ("demos") of our products at one of our customer's store locations (in the branded nutraceutical products segment). We had no such expenses in the six months ended December 31, 2013 due to the lack of sales to this customer in the six months ended December 31, 2013.

Our professional and consulting fees decreased by approximately \$0.1 million in the six months ended December 31, 2013 compared to the six months ended December 31, 2012 as we did not have any significant legal matters to address in the six months ended December 31, 2013 compared to the six months ended December 31, 2012.

Other expense, net. Other expense, net was approximately \$0.5 million in each of the six months ended December 31, 2013 and 2012, and is composed of:

	Six months ended December 31,	
	2013	2012
	(dollars in thousands)	
Interest expense	\$ (494)	\$ (487)
Other (expense) income:		
Change in fair value of derivative instruments	9	(428)
Other income, net, primarily recovery	5	374
Other expense, net	<u>\$ (480)</u>	<u>\$ (541)</u>

The change in fair value of derivative liabilities was mainly the result of the increase in the trading price of our common stock from \$0.15 as of June 30, 2013 to \$0.19 as of December 31, 2013. The closing trading price of our stock is one of the variables used to calculate the estimated fair value of our derivative liabilities associated with the underlying derivative instruments. In the six months ended December 31, 2012, we recovered approximately

\$0.4 million in gross profits as a result of manufacturing defects in our products purchased from the contract manufacturer that we could not sell through to our customers.

Federal and state income tax, net. For the six months ended December 31, 2013 and 2012, we had a minimal amount of state tax expenses, \$104,000 and \$13,000, respectively. We continue to maintain a full reserve on our deferred tax assets as it has been determined that based upon past losses, our past liquidity concerns and the current economic environment, that it is “more likely than not” our deferred tax assets may not be realized. A significant portion of our deferred tax assets relate to our federal net operating loss carryforwards. We file consolidated federal tax returns and although we currently have net income for book purposes, we have not been able to determine whether it is more likely than not that we will be able to use this asset in the future taxable years. For the six months ended December 31, 2013, the current federal tax provision was offset by the utilization of the federal net operating loss carryforwards and a corresponding release of the related valuation reserve.

Net income (loss). Our net income for the six months ended December 31, 2013 was \$0.7 million as compared to a net loss of \$0.2 million for the six months ended December 31, 2012. The change from a net loss to net income of approximately \$0.9 million was primarily the result of increased operating income of \$0.9 million.

For the Three Months Ended December 31, 2013 compared to the Three Months Ended December 31, 2012

Sales, net. Sales, net, for the three months ended December 31, 2013 and 2012 were \$8.8 million and \$7.4 million, respectively, an increase of 19%, and are comprised of the following:

	<u>Three months ended</u> <u>December 31,</u>		<u>Dollar</u> <u>Change</u>	<u>Percentage</u> <u>Change</u>
	<u>2013</u>	<u>2012</u>	<u>2013 vs 2012</u>	<u>2013 vs 2012</u>
	<i>(amounts in thousands)</i>			
Contract Manufacturing:				
US Customers	\$ 4,973	\$ 3,521	\$ 1,452	41.2%
International Customers	2,819	2,709	110	4.1%
Net sales, Contract Manufacturing	<u>7,792</u>	<u>6,230</u>	<u>1,562</u>	<u>25.1%</u>
Branded Nutraceutical Products:				
US Customers	130	403	(273)	(67.7%)
International Customers	322	391	(69)	(17.6%)
Net sales, Branded Nutraceutical Products	<u>452</u>	<u>794</u>	<u>(342)</u>	<u>(43.1%)</u>
Other Nutraceuticals:				
US Customers	515	346	169	48.8%
International Customers	29	25	4	16.0%
Net sales, Other Nutraceuticals	<u>544</u>	<u>371</u>	<u>173</u>	<u>46.6%</u>
Total net sales	<u>\$ 8,788</u>	<u>\$ 7,395</u>	<u>\$ 1,393</u>	<u>18.8%</u>

For the three months ended December 31, 2013, approximately 82% of total net sales were derived from two customers in our contract manufacturing segment as compared to approximately 73% of total net sales from the same two customers in our contract manufacturing segment for the three months ended December 31, 2012. The loss of either of these customers could have an adverse affect on our operations.

The increase in our net sales is primarily the result of an increase of approximately \$1.6 million in our contract manufacturing segment primarily due to increased sales volumes to our two major customers in the three months ended December 31, 2013, offset in part, by a decrease in the volume of sales in our branded proprietary products segment of \$0.3 million, primarily from our club store distribution channels.

Cost of sales. Cost of sales increased by \$1.1 million to \$7.4 million for the three months ended December 31, 2013, as compared to \$6.3 million for the three months ended December 31, 2012. Cost of sales as a percentage of net sales was substantially the same, approximately 84% for each of the three months ended December 31,

2013 and 2012. The increase in the cost of sales amount, 17% over the comparable prior period, was primarily the result of increased sales of approximately 19%.

Selling and Administrative Expenses. Selling and administrative expenses were \$0.8 million for the three months ended December 31, 2013, as compared to \$1.1 million for the three months ended December 31, 2012, a decrease of approximately \$0.3 million or 23%. As a percentage of sales, net, selling and administrative expenses were 9.9% for the three months ended December 31, 2013 and 14.5% for the prior comparable period.

The net decrease in selling and administrative expenses of \$0.3 million is mainly due to decreases in advertising and other marketing expenses of \$0.1 million. Other selling and administrative expenses such as employee costs, warehouse, office expenses, professional fees, commissions and other expenses as a group decreased by approximately \$0.1 million, with each individual classification decreasing by less than \$65,000 from the prior comparable period.

Our advertising and marketing costs decreased by approximately \$0.1 million in the three months ended December 31, 2013 compared to the three months ended December 31, 2012 primarily as a result of a decrease in in-store demonstrations of our products at one of our customer's store locations in our branded nutraceutical products segment. We had no such expenses in the three months ended December 31, 2013 due to the lack of sales to this customer in the three months ended December 31, 2013.

Other income (expense), net. Other income (expense), net was approximately \$0.2 million of other expense, net for the three months ended December 31, 2013 compared to approximately \$0.8 million other income, net for the three months ended December 31, 2012, and is composed of:

	Three months ended December 31,	
	2013	2012
	(dollars in thousands)	
Interest expense	\$ (246)	\$ (239)
Other (expense) income:		
Change in fair value of derivative instruments	82	656
Other income, net, primarily recovery	3	380
Other income (expense), net	<u>\$ (161)</u>	<u>\$ 797</u>

The change in fair value of derivative liabilities for the three months ended December 31, 2013 was not a significant change from the previous three month period ended September 30, 2013 as the trading price of our common stock was \$0.20 as of September 30, 2013 compared to \$0.19 as of December 31, 2013 as compared to the comparable three months ended December 31, 2012 when the trading price of our common stock was \$0.25 as of September 30, 2012 to \$0.16 as of December 31, 2012. The closing trading price of our stock is one of the variables used to calculate the estimated fair value of our derivative liabilities associated with the underlying derivative instruments. In the three months ended December 31, 2012, we recovered approximately \$0.4 million in gross profits, as a result of manufacturing defects in our products purchased from the contract manufacturer that we could not sell through to our customers in our branded proprietary products segment.

Federal and state income tax, net. For the three months ended December 31, 2013 and 2012, we had a minimal amount of state tax expenses, \$61,000 and \$11,000, respectively. We continue to maintain a full reserve on our deferred tax assets as it has been determined that based upon past losses, our past liquidity concerns and the current economic environment, that it is "more likely than not" our deferred tax assets may not be realized. A significant portion of our deferred tax assets relate to our federal net operating loss carryforwards. We file consolidated federal tax returns and although we currently have net income for book purposes, we have not been able to determine whether it is more likely than not that we will be able to use this asset in the future taxable years. For the three months ended December 31, 2013, the current federal tax provision was offset by the utilization of the federal net operating loss carryforwards and a corresponding release of the related valuation reserve.

Net income. Our net income for the three months ended December 31, 2013 was \$0.4 million compared to \$0.8 million for the three months ended December 31, 2012, a net decrease of \$0.4 million. The net decrease in our net income is primarily the result of the increase in our operating income of \$0.6 million, offset by a decrease in other income (expense), net of \$1.0 million. The decrease in other income (expense), net was primarily from the decrease in the change in the fair value of derivative liabilities of \$0.6 million from the three months ended December 31, 2012 compared to the three months ended December 31, 2013 and the decrease in other income of \$0.4 million, which in the three months ended December 31, 2012 represented the recovery of gross profits from our then contract manufacturer for our branded propriety products segment.

Seasonality

The nutraceutical business tends to be seasonal. We have found that in our first fiscal quarter ending on September 30th of each year, orders for our branded proprietary nutraceutical products usually slow (absent the addition of new customers or a new product launch with a significant first time order), as buyers in various markets may have purchased sufficient inventory to carry them through the summer months. Conversely, in our second fiscal quarter, ending on December 31st of each year, orders for our products increase as the demand for our branded nutraceutical products seems to increase in late December to early January as consumers become health conscious as they enter the new year.

The Company believes that there are other non-seasonal factors that also may also influence the variability of quarterly results including, but not limited to, general economic and industry conditions that affect consumer spending, changing consumer demands and current news on nutritional supplements. Accordingly, a comparison of the Company's results of operations from consecutive periods is not necessarily meaningful, and the Company's results of operations for any period are not necessarily indicative of future periods.

Liquidity and Capital Resources

The following table sets forth, for the periods indicated, the Company's net cash flows used in operating, investing and financing activities, its period end cash and cash equivalents and other operating measures:

	For the six months ended December 31,	
	2013	2012
	<i>(dollars in thousands)</i>	
Net cash provided by (used in) operating activities	\$ 1,000	\$ (979)
Net cash (used in) provided by investing activities	\$ (29)	\$ 10
Net cash (used in) provided by financing activities	\$ (891)	\$ 948
Cash at end of period	\$ 135	\$ 124

At December 31, 2013, our working capital deficit was approximately \$1.8 million, a decrease of approximately \$0.7 million in our working capital deficit of approximately \$2.5 million at June 30, 2013. Our current assets decreased by approximately \$0.7 million and our current liabilities decreased by approximately \$1.3 million.

Net cash provided by operating activities of \$1.0 million in the six months ended December 31, 2013, includes net income of approximately \$0.7 million. After excluding the effects of non-cash expenses, including depreciation and amortization, and changes in the fair value of derivative liabilities, the adjusted cash provided from operations before the effect of the changes in working capital components was \$1.0 million. Cash was provided by operations from our working capital assets and liabilities in the amount of approximately \$3,000 and was primarily the result of decreases in accounts receivable of \$0.1 million and inventories of \$0.6 million offset, in part, by a net decrease in accounts payable and accrued expenses and other liabilities of approximately \$0.8 million.

Net cash used in operating activities of \$1.0 million in the six months ended December 31, 2012, includes net loss of approximately \$0.2 million. After excluding the effects of non-cash expenses, including depreciation and amortization, and changes in the fair value of derivative liabilities, the adjusted cash provided from operations before the effect of the changes in working capital components was \$0.6 million. Cash was used in operations from our working capital assets and liabilities in the amount of approximately \$1.5 million and was primarily the result of increases in accounts receivable of \$0.9 million and inventories of \$1.2 million offset, in part, by a net increase in accounts payable and accrued expenses and other liabilities of approximately \$0.4 million.

Cash used in investing activities of \$29,000 in the six months ended December 31, 2013 was for the purchase of property and equipment primarily in our contract manufacturing segment. Cash provided by investing activities in the six months ended December 31, 2012 was from the sale of machinery and equipment for \$18,000, offset by the use of cash for the purchase of fixed assets of approximately \$8,000.

Cash used in financing activities was approximately \$0.9 million for the three months ended December 31, 2013, \$17.8 million for payments under our revolving credit facility and repayments of principal under our term note in the amount of \$0.6 million, offset by advances under our revolving credit facility of \$17.5 million.

Cash provided by financing activities was approximately \$0.9 million for the six months ended December 31, 2012, \$17.0 million from advances under our revolving credit facility offset by payments under our revolving credit facility of \$15.9 million and repayments of principal under our term note in the amount of \$0.2 million.

As of December 31, 2013, we had cash of \$0.1 million, funds available under our revolving credit facility of approximately \$0.6 million and a working capital deficit of \$1.8 million. Our working capital deficit includes \$4.2 million outstanding under our revolving line of credit which is not due until July 2017 but classified as current due to a subjective acceleration clause that could cause the advances to become currently due. (See Note 5 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q). Furthermore, we had income from operations of approximately \$1.3 million in the six months ended December 31, 2013. After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements through the period ending December 31, 2014.

Our total annual commitments at December 31, 2013 for long term non-cancelable leases of approximately \$608,000 consists of obligations under operating leases for facilities and operating lease agreements for the rental of warehouse equipment, office equipment and automobiles.

On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent us a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company. In the Demand Letter, Cedarburg demanded payment by us of \$0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA. In addition, in the Demand Letter, Cedarburg informed us that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of \$0.3 million.

On May 30, 2012, we sent a letter responding to the Demand Letter and setting forth our position that we have no obligation to indemnify Cedarburg as demanded. On June 18, 2012, Cedarburg responded to our letter and, on July 27, 2012, we sent another letter to Cedarburg reiterating our position that we have no obligation to indemnify Cedarburg as demanded. On December 18, 2012, Cedarburg responded to our letter and, on January 15, 2013, we sent another letter to Cedarburg reiterating our position that we have no obligation to indemnify Cedarburg as demanded. As of February 12, 2014, we have not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter. We intend to vigorously contest Cedarburg's demand as set forth in the Demand Letter.

Capital Expenditures

The Company's capital expenditures for the six months ended December 31, 2013 and 2012 were approximately \$105,000 (\$76,000 funded with capitalized lease financing) and \$8,000, respectively. The Company has budgeted approximately \$0.5 million for capital expenditures for fiscal 2013. The total amount is expected to be funded from cash provided from the Company's operations and from lease financing.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Recent Accounting Pronouncements

None.

Impact of Inflation

The Company does not believe that inflation has significantly affected its results of operations.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

Item 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended (the "Exchange Act") is recorded, processed, summarized, and reported within the time periods specified by the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the Company has evaluated the effectiveness of its disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2013, and, based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these controls and procedures are effective in providing reasonable assurance of compliance.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during the three and six months ended December 31, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

None.

Item 1A. Risk Factors

The risks described in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended June 30, 2013, could materially and adversely affect our business, financial condition and results of operations. The risk factors discussed in that Form 10-K do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. There have been no material changes to our risk factors from those disclosed in our Form 10-K for the year ended June 30, 2013.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURE

Not Applicable.

Item 5. OTHER INFORMATION

None.

Item 6. EXHIBITS

(a) Exhibits

Exhibit Number

31.1	Certification of pursuant to Section 302 of Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
31.2	Certification of pursuant to Section 302 of Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
32.1	Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
32.2	Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
101	The following financial information from Integrated BioPharma, Inc.'s Quarterly Report on Form 10-Q for the quarter ended December 31, 2013, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2013 and 2012, (ii) Condensed Consolidated Balance Sheets as of December 31, 2013 and June 30, 2013, (iii) Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2013 and 2012, and (iv) the Notes to Condensed Consolidated Statements.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTEGRATED BIOPHARMA, INC.

Date: February 12, 2014

By: /s/ E Gerald Kay
E, Gerald Kay,
President and Chief Executive Officer

Date: February 12, 2014

By: /s/ Dina L. Masi
Dina L. Masi,
Chief Financial Officer & Senior Vice President

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, E. Gerald Kay certify that:

1. I have reviewed this quarterly report on Form 10-Q of Integrated BioPharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 12, 2014

By: /s/ E. Gerald Kay

Name: E. Gerald Kay

Title: President and Chief Executive Officer

Certification of Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Dina L. Masi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Integrated BioPharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 12, 2014

By: /s/ Dina L. Masi

Name: Dina L. Masi

Title: Chief Financial Officer & Senior Vice President

CERTIFICATION OF PERIODIC REPORT

As adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended December 31, 2013 of Integrated BioPharma, Inc. (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), E. Gerald Kay, the President and Chief Executive Officer of Integrated BioPharma, Inc. certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to his knowledge:

- (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification accompanies the Report pursuant to Section 906 of Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: February 12, 2014

By: /s/ E. Gerald Kay
E. Gerald Kay
President and Chief Executive Officer

CERTIFICATION OF PERIODIC REPORT

As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended December 31, 2013 of Integrated BioPharma, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Dina L. Masi, the Senior Vice President and Chief Financial Officer of Integrated BioPharma, Inc. certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to her knowledge:

- (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification accompanies the Report pursuant to Section 906 of Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: February 12, 2014

By: /s/ Dina L. Masi
Dina L. Masi
Chief Financial Officer & Senior Vice President